STRO vs XLI
Sutro Biopharma (STRO) versus XLI (XLI) — a side-by-side from cached financials, not a winner call.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
XLI (XLI) common stock.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
XLI does not have a complete income-statement cache yet.
STRO currently screens at market cap $470.8M. XLI currently screens at market cap $0.
Not investment advice. Open the STRO and XLI stock pages for the full models.
Not investment advice.